Top

Published in:

01-07-2013 | Brief Report

HCV infection among cocaine users in the state of Pará, Brazilian Amazon

Authors: Aldemir B. Oliveira-Filho, Leila Sawada, Laine C. Pinto, Daiane Locks, Santana L. Bahia, I. Brasil-Costa, José Alexandre R. Lemos

Published in: Archives of Virology | Issue 7/2013

Abstract

In this study, the prevalence, genotype frequency, and risk factors for HCV infection in 384 cocaine users were determined. One hundred twenty-four (32.3 %) cocaine users had anti-HCV antibodies and 120 (31.3 %) had HCV-RNA. Genotyping results indicated the predominance of genotypes 1 (73.3 %) and 3 (26.7 %). Multivariate analysis showed an association of HCV infection with tattoos, shared use of paraphernalia, daily cocaine use, and a long history of cocaine use. The epidemiological aspects of HCV infection among cocaine users presented here should serve as an incentive for the establishment of a program of hepatitis C prevention and control by the local public-health authorities in the Amazon.

Aaron S, McMahon JM, Milano D et al (2008) Intranasal transmission of hepatitis C virus: virological and clinical evidence. Clin Infect Dis 47:931–934PubMedCrossRef

Aceijas C, Rhodes T (2007) Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 18:352–358PubMedCrossRef

Allison RD, Conry-Cantilena C, Koziol D et al (2012) A 25-year study of the clinical and histologic outcomes of hepatitis C virus infection and its modes of transmission in a cohort of initially asymptomatic blood donors. J Infect Dis 206:654–661PubMedCrossRef

Alter MJ (2007) Epidemiology of hepatitis C virus infection. World J Gastroenterol 13:2436–2441PubMed

Amon JJ, Garfein RS, Ahdieh-Grant L et al (2008) Prevalence of Hepatitis C Virus Infection among Injection Drug Users in the United States, 1994–2004. Clin Infect Dis 46:1852–1858PubMedCrossRef

Caiaffa WT, Zocratto KF, Osimani ML et al (2010) Hepatitis C virus among non-injecting cocaine users (NICUs) in South America: can injectors be a bridge? Addiction 106:143–151PubMedCrossRef

Campiotto S, Pinho JR, Carrilho FJ et al (2005) Geographic distribution of hepatitis C virus genotypes in Brazil. Braz J Med Biol Res 38:41–49PubMedCrossRef

Campollo O, Roman S, Panduro A et al (2012) Non-injection drug use and hepatitis C among drug treatment clients in west central Mexico. Drug Alcohol Depend 123:269–272PubMedCrossRef

Carvalho HB, Seibel SD, Burattini MN, Massad E, Reingold A (2003) Hepatitis B and C and syphilis vulnerability related infections among institutionalized disadvantaged youth in São Paulo-Brazil. J Bras Doenças Sex Transm 15:41–45

10.

Fischer B, Powis J, Firestone Cruz M (2008) Hepatitis C virus transmission among oral crack users: viral detection on crack paraphernalia. Eur J Gastroenterol Hepatol 20:29–32PubMedCrossRef

11.

Galperim B, Cheinquer H, Stein A et al (2004) Intranasal cocaine use does not appear to be an independent risk factor for HCV infection. Addiction 99:973–977PubMedCrossRef

12.

Gelberg L, Robertson MJ, Arangua L et al (2012) Prevalence, distribution, and correlates of hepatitis C virus infection among homeless adults in Los Angeles. Public Health Rep 127:407–421PubMed

13.

Hermanstyne KA, Bangsberg DR, Hennessey K et al (2012) The association between use of non-injection drug implements and hepatitis C virus antibody status in homeless and marginally housed persons in San Francisco. J Public Health (Oxf) 34:330–339CrossRef

14.

Jafari S, Copes R, Baharlou S et al (2010) Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. doi:10.1016/j.ijid.2010.03.019

15.

Lopes CL, Teles SA, Espírito-Santo MP et al (2009) Prevalence, risk factors and genotypes of hepatitis C virus infection among drug users, Central-Western Brazil. Rev Saude Publica 43:43–50PubMedCrossRef

16.

Macías J, Palacios RB, Claro E et al (2008) High prevalence of hepatitis C virus infection among non-injecting drug users: association with sharing the inhalation implements of crack. Liver Int 28:781–786PubMedCrossRef

17.

Martinez A, Talal AH (2008) Non-injection drug use: an under-appreciated risk factor for hepatitis C virus transmission. Liver Int 28:757–760PubMedCrossRef

18.

Martins T, Narciso-Schiavon JL, Schiavon LL (2011) Epidemiology of hepatitis C virus infection. Rev Assoc Med Bras 57:107–112PubMedCrossRef

19.

McMahon JM, Tortu S (2003) A potential hidden source of hepatitis C infection among non-injecting drug users. J Psychoactive Drugs 35:455–460PubMedCrossRef

20.

McMahon JM, Simm M, Milano D, Clatts M (2004) Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob. doi:10.1186/1476-0711-3-6 PubMed

21.

Morice Y, Cantaloube JF, Beaucourt S et al (2006) Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol 78:1296–1303PubMedCrossRef

22.

Murakami J, Nagata I, Iitsuka T et al (2012) Risk factors for mother-to-child transmission of hepatitis C virus: Maternal high viral load and fetal exposure in the birth canal. Hepatol Res 42:648–657PubMedCrossRef

23.

Novais AC, Lopes CL, Reis NR et al (2009) Prevalence of hepatitis C virus infection and associated factors among male illicit drug users in Cuiabá, Mato Grosso, Brazil. Mem Inst Oswaldo Cruz 104:892–896PubMedCrossRef

24.

Oliveira-Filho AB, Pimenta AS, Rojas MF et al (2010) Likely transmission of hepatitis C virus through sharing of cutting and perforating instruments in blood donors in the State of Pará, Northern Brazil. Cad Saude Publica 26:837–844PubMedCrossRef

25.

Oliveira-Filho AB, Pimenta AS, Rojas MF et al (2010) Prevalence and genotyping of hepatitis C virus in blood donors in the state of Pará, Northern Brazil. Mem Inst Oswaldo Cruz 105:103–106PubMedCrossRef

26.

Oliveira-Filho AB, Oliveira EH, Castro JAA, Silva LV, Vallinoto ACR, Lemos JAR (2012) Epidemiological aspects of HCV infection in HIV-infected individuals in Piauí State Northeast Brazil. Arch Virol. doi:10.1007/s00705-012-1435-3 PubMed

27.

Prati D (2006) Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 45:607–616PubMedCrossRef

28.

Sawada L, Pinheiro AC, Locks D et al (2011) Distribution of hepatitis C virus genotypes among different exposure categories in the State of Pará, Brazilian Amazon. Rev Soc Bras Med Trop 44:8–12PubMedCrossRef

29.

Scheinmann R, Hagan H, Lelutiu-Weinberger C et al (2007) Non-injection drug use and Hepatitis C Virus: a systematic review. Drug Alcohol Depend 89:1–12PubMedCrossRef

30.

Segurado AC, Braga P, Etzel A, Cardoso MR (2004) Hepatitis C virus coinfection in a cohort of HIV-infected individuals from Santos, Brazil: seroprevalence and associated factors. AIDS Patient Care STDS 18:135–143PubMedCrossRef

31.

Silva MB, Andrade TM, Silva LK et al (2010) Prevalence and genotypes of hepatitis C virus among injecting drug users from Salvador-BA, Brazil. Mem Inst Oswaldo Cruz 105:299–303PubMedCrossRef

32.

Terrault NA, Dodge JL, Murphy EL et al (2012) Sexual transmission of HCV among monogamous heterosexual couples: the HCV partners study. Hepatology. doi:10.1002/hep.26164 PubMed

33.

van den Berg CH, van de Laar TJ, Kok A et al (2009) Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam Cohort Studies. J Viral Hepat 16:568–577PubMedCrossRef

34.

Wang CC, Krantz E, Klarquist J et al (2007) Acute hepatitis C in a contemporary US cohort: modes of acquisition and factors influencing viral clearance. J Infect Dis 196:1474–1482PubMedCrossRef

35.

Xia X, Luo J, Bai J, Yu R (2008) Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 122:990–1003PubMedCrossRef

Title: HCV infection among cocaine users in the state of Pará, Brazilian Amazon
Authors: Aldemir B. Oliveira-Filho
Leila Sawada
Laine C. Pinto
Daiane Locks
Santana L. Bahia
I. Brasil-Costa
José Alexandre R. Lemos
Publication date: 01-07-2013
Publisher: Springer Vienna
Published in: Archives of Virology / Issue 7/2013
Print ISSN: 0304-8608
Electronic ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-013-1627-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection

Molecular epidemiology and phylogenetic analysis of porcine epidemic diarrhea virus (PEDV) field isolates in Korea

Microarray analysis of differentially expressed transcripts in porcine intestinal epithelial cells (IPEC-J2) infected with porcine sapelovirus as a model to study innate immune responses to enteric viruses

Molecular characterization of HetRV8-ir1, a partitivirus of the invasive conifer pathogenic fungus Heterobasidion irregulare

Genomic classification of betanodavirus by molecular phylogenetic analysis of the coat protein gene

The complete genomic sequence of a novel mycovirus from Rhizoctonia solani AG-1 IA strain B275

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials